<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077465</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-368-1212</org_study_id>
    <nct_id>NCT02077465</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple
      infusions of GS-5745 in participants with chronic obstructive pulmonary disease (COPD) as
      assessed by adverse events (AEs) and laboratory abnormalities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events, change from screening in laboratory tests and vital signs, and development of immunogenicity after dosing</measure>
    <time_frame>Baseline to Day 29 plus 30 days</time_frame>
    <description>This composite endpoint will measure the safety and tolerability profile of GS-5745.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of GS-5745 as measured by AUC and Cmax</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>AUC represents the total amount of drug absorbed by the body by comparing plasma concentration over time
Cmax is defined as the maximum concentration of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of GS-5745 as measured by Tmax, Clast, Tlast, Ctau, λz, CL, and Vz</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Tmax is defined as the time of Cmax
Clast is defined as the last observable concentration of drug
Tlast is defined as the time of Clast
Ctau is defined as the observed drug concentration at the end of the dosing interval
λz is defined as the terminal elimination rate constant
CL is defined as systemic clearance following intravenous (IV) administration
Vz is defined as apparent volume of distribution following IV administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>GS-5745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match GS-5745</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5745</intervention_name>
    <description>400 mg GS-5745 administered intravenously</description>
    <arm_group_label>GS-5745</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match GS-5745</intervention_name>
    <description>Placebo to match GS-5745 administered intravenously</description>
    <arm_group_label>Placebo to match GS-5745</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight: ≥ 45 kg to &lt; 120 kg at screening

          -  Males or non-pregnant, non-lactating females

          -  Male subjects and female subjects of childbearing potential who engage in heterosexual
             intercourse must agree to use protocol specified method(s) of contraception. Male
             subjects must refrain from sperm donation for 90 days post last infusion of the study
             drug

          -  Diagnosis of COPD per Global Initiative for Chronic Obstructive Lung Disease (GOLD)
             guidelines for at least 6 months prior to screening and anticipated to remain on
             stable therapy for the duration of the study

          -  Post-bronchodilator forced expiratory volume in one second (FEV1) ≥ 40% predicted

          -  No changes in COPD medications within 30 days prior to randomization

          -  Hepatic panel [aspartate aminotransferase (AST), alanine aminotransferase (ALT), total
             bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase (LDH)] ≤ 2
             times the upper limit of the normal range (ULN)

          -  Serum creatinine ≤ 2.0

          -  Hemoglobin ≥ 8.5 g/dL (both males and females)

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 mm^3)

          -  Platelets ≥ 100 x 10^9/L

        Exclusion Criteria:

          -  Clinically significant active infection as judged by the investigator during screening

          -  Known history of HIV, hepatitis B or C during screening. Subjects who are hepatitis B
             surface antigen positive, but who received a successful series of hepatitis B
             vaccinations and never had the disease remain eligible

          -  A positive QuantiFERON-TB GOLD test during screening

          -  History of malignancy within the last 5 years except for patients who have been
             treated locally for non-melanoma skin cancer or cervical carcinoma in situ

          -  Any serious cardiac event such as myocardial infarction, unstable or life-threatening
             arrhythmia, hospitalization for cardiac failure within 6 months prior to randomization
             or any significant or new electrocardiogram (ECG) finding at Visit 1 as judged by the
             Investigator

          -  A hospitalization for a respiratory event such as, but not limited to, COPD,
             pneumonia, bronchiolitis, within the previous 6 months prior to randomization

          -  Chronic lung disease other than COPD such as: asthma, cystic fibrosis or fibrotic
             disease, α-1-antitrypsin deficiency, interstitial lung disease, pulmonary
             thromboembolic disease, or bronchiectasis

          -  Chronic use of systemic corticosteroids and/or treatment with systemic corticosteroids
             for an acute exacerbation of COPD (AECOPD) event, or other medical condition not
             requiring hospitalization, within 90 days of randomization.

          -  Treatment with antibiotics for an AECOPD event, or other medical condition not
             requiring hospitalization within 90 days of randomization, or any minor medical event
             not requiring hospitalization within 14 days of randomization.

          -  Treatment with any marketed or investigational biologic within 5 half-lives of the
             molecule or if unknown within 90 days of screening

          -  Subjects currently on nonbiologic immune modulator medications such as: azathioprine,
             cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate mofetil,
             sulfasalazine, tofacitinib, within 90 days of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gossage, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Buffalo CTRC</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, chronic obstructive pulmonary disease; Phase 1b, Safety, Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

